, Volume 72, Issue 7, pp 873–879 | Cite as

Coming to Terms with Nonsteroidal Anti-Inflammatory Drug Gastropathy

  • Sanford H. RothEmail author
Current Opinion


Despite well known complications, oral nonsteroidal anti-inflammatory drugs (NSAIDs) remain the most commonly prescribed medications in the US for musculoskeletal disorders such as osteoarthritis. Although there has been a recent focus on the cardiovascular and renal complications associated with these agents, NSAID gastropathy continues to be a particular concern in many patients, especially those at increased risk for serious adverse events, including the elderly. Complicating the diagnosis of NSAID gastropathy is its silent course, which, up to half of the time, is asymptomatic. Several strategies are currently employed by physicians to mitigate the risk of serious gastrointestinal events. These include either addition of a proton pump inhibitor to current nonselective NSAID therapy or the use of a cyclo-oxygenase-2—selective NSAID. Although these agents are effective at mitigating the overall risk of gastrointestinal adverse events, they fail to address NSAID-related cardiovascular and renal risks. Due to their reduced systemic absorption, topical NSAIDs may present a viable option for patients at increased risk for serious NSAID-related adverse events, including gastropathy.


Celecoxib Peptic Ulcer Disease Esomeprazole Gastrointestinal Adverse Event Boxed Warning 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Technical editorial and medical writing assistance for the preparation of this manuscript was provided by Lauren Burawski, MA, Synchrony Medical LLC, West Chester, PA, USA. Funding for this support was provided by Mallinckrodt Inc., a Covidien company, Hazelwood, MO, USA.

Dr Roth is a current stakeholder in Transdel Pharmaceuticals and serves as a consultant and speaker for Covidien.


  1. 1.
    Roth SH. Nonsteroidal anti-inflammatory drug gastropathy. We started it — can we stop it?. Arch Intern Med 1986 Jun; 146 (6): 1075–6Google Scholar
  2. 2.
    Lanas A, Garcia-Tell G, Armada B, et al. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk of cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med 2011 Apr 14; 9: 38Google Scholar
  3. 3.
    Roth SH, Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy: recognition and response. Arch Intern Med 1987 Dec; 147 (12): 2093–100PubMedCrossRefGoogle Scholar
  4. 4.
    Sun DC, Roth SH, Mitchell CS, et al. Upper gastrointestinal disease in rheumatoid arthritis. Am J Dig Dis 1974 May; 19 (5): 405–10PubMedCrossRefGoogle Scholar
  5. 5.
    US FDA. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Medical product safety information. COX-2 selective and non-selective non-steroidal anti-inflammatory drugs NSAIDs [online]. Available from URL: [Accessed 2012 Feb 24]
  6. 6.
    Melo Gomes JA, Roth SH, Zeeh J, et al. Doubleblind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993 Dec; 52 (12): 881–5PubMedCrossRefGoogle Scholar
  7. 7.
    Larkai EN, Smith JL, Lidsky MD, et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987 Nov; 82 (11): 1153–8PubMedGoogle Scholar
  8. 8.
    Coles LS, Fries JF, Kraines RG, et al. From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med 1983 May; 74 (5): 820–8PubMedCrossRefGoogle Scholar
  9. 9.
    Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987 May; 28 (5): 527–32PubMedCrossRefGoogle Scholar
  10. 10.
    Masso Gonzalez EL, Pastrignani P, Tacconelli S, et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010 Jun; 62 (6): 1592–601PubMedCrossRefGoogle Scholar
  11. 11.
    Richette P, Hilliquin P, Bertin P, et al. Comparison of general practitioners and rheumatologists’ prescription patterns for patients with knee osteoarthritis. BMC Musculoskelet Disord 2011 Apr; 12: 72Google Scholar
  12. 12.
    Roth SH. Understanding the COX-2/NSAID dilemma. Drugs 2005; 65 (14): 1915–7PubMedCrossRefGoogle Scholar
  13. 13.
    Roth SH. From peptic ulcer disease to NSAID gastropathy: an evolving nosology. Drugs Aging 1995 May; 6 (5): 358–67PubMedCrossRefGoogle Scholar
  14. 14.
    Manguso F, Riccio E, de Nucci G, et al. Helicobacter pylori infection in bleeding peptic ulcer patients after non-steroidal antiinflammatory drug consumption. World J Gastroenterol 2011 Oct 28; 17 (40): 4509–16PubMedCrossRefGoogle Scholar
  15. 15.
    Chan FK, Leung WK. Peptic-ulcer disease. Lancet 2002 Sep 21; 360 (9337): 933–41PubMedCrossRefGoogle Scholar
  16. 16.
    Najm WI. Peptic ulcer disease. Prim Care 2011 Sep; 38 (3): 383–94PubMedCrossRefGoogle Scholar
  17. 17.
    Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epide-miologic studies published in the 1990s. Arch Intern Med 2000 Jul 24; 160 (14): 2093–9PubMedCrossRefGoogle Scholar
  18. 18.
    Tarone RE, Blot WJ, McLaughlin JK. Nonselective nonaspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: relative and absolute risk estimates from recent epidemiologic studies. Am J Ther 2004 Jan–Feb; 11 (1): 17–25PubMedCrossRefGoogle Scholar
  19. 19.
    Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA 2000 Sep 13; 284 (10): 1247–55Google Scholar
  20. 20.
    Bardou M, Barkun AN. Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: from risk factor identification to risk factor intervention. Joint Bone Spine 2010 Jan; 77 (1): 6–12PubMedCrossRefGoogle Scholar
  21. 21.
    Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part II. OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008 Dec; 16 (12): 137–62CrossRefGoogle Scholar
  22. 22.
    Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012 April; 64 (4): 465–74CrossRefGoogle Scholar
  23. 23.
    Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003 Dec; 62 (12): 1145–55Google Scholar
  24. 24.
    Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis 2011 May; 70 (5): 818–22PubMedCrossRefGoogle Scholar
  25. 25.
    American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009 Aug; 57 (8): 1331–46CrossRefGoogle Scholar
  26. 26.
    American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee (non-arthroplasty), 2008 [online]. Available from URL: [Accessed 2011 Jul 26]
  27. 27.
    National Institute for Health and Clinical Excellence. Osteoarthritis: the care and management of osteoarthritis in adults. NICE clinical guideline 59. London: NICE, 2008Google Scholar
  28. 28.
    Wilcox CM, Cryer B, Triadafilopoulos G. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. J Rheumatol 2005 Nov; 32 (11): 2218–24PubMedGoogle Scholar
  29. 29.
    Rostom A, Muir K, Dube C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007 Jul; 5 (7): 818–28PubMedCrossRefGoogle Scholar
  30. 30.
    Funk CD, Fitz Gerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007 Nov; 50 (5): 470–9PubMedCrossRefGoogle Scholar
  31. 31.
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000 Nov 23; 343 (21): 1520–8PubMedCrossRefGoogle Scholar
  32. 32.
    Sun SX, Lee KY, Bertram CT, et al. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Curr Med Res Opin 2007 Aug; 23 (8): 1859–66PubMedCrossRefGoogle Scholar
  33. 33.
    Pavlicevic I, Kuzmanic M, Rumboldt M, et al. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol 2008 Fall; 15 (3): e372-82Google Scholar
  34. 34.
    McGettigan P, Henry D. Cardiovascular risk with nonsteroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. Plos Med 2011 Sep; 8 (9): e1001098Google Scholar
  35. 35.
    Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011 Jan 11; 342: c7086Google Scholar
  36. 36.
    Patterson R, Bello AE, Lefkowith J. Immunologic toler-ability profile of celecoxib. Clin Ther 1999 Dec; 21 (12): 2065–79PubMedCrossRefGoogle Scholar
  37. 37.
    Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007 May 12; 369 (9573): 1621–6PubMedCrossRefGoogle Scholar
  38. 38.
    Ares JJ, Outt PE. Gastroprotective agents for the prevention of NSAID-induced gastropathy. Curr Pharm Des 1998 Feb; 4 (1): 17–36PubMedGoogle Scholar
  39. 39.
    Hochberg MC, Fort JG, Svensson O, et al. Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr Med Res Opin 2011 Jun; 27 (6): 1243–53PubMedCrossRefGoogle Scholar
  40. 40.
    Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006 Dec 27; 296 (24): 2947–53PubMedCrossRefGoogle Scholar
  41. 41.
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005 Aug 4; 353 (5): 487–97PubMedCrossRefGoogle Scholar
  42. 42.
    Duexis® (ibuprofen and famotidine) [package insert]. Hunt Valley (MD): Pharmaceutics International, Inc., 2011Google Scholar
  43. 43.
    Weinblatt ME, Genovese MC, Klivitz AJ, et al. Efficacy, safety and tolerability of HZT-501, including users of low-dose aspirin, a single-tablet combination of ibuprofen-famotidine: results of two phase 3 trials [abstract]. Arthritis Rheum 2010; 62 Suppl. 10: 945Google Scholar
  44. 44.
    Voltaren® gel (diclofenac sodium topical gel) 1% [package insert]. Chadds Ford (PA): Endo Pharmaceuticals Inc., 2009Google Scholar
  45. 45.
    PENNSAID® (diclofenac sodium topical solution) 1.5% w/w [package insert]. Hazelwood (MO): Mallinckrodt Inc., 2010 JunGoogle Scholar
  46. 46.
    Moen MD. Topical diclofenac solution. Drugs 2009; 69 (18): 2621–32PubMedCrossRefGoogle Scholar
  47. 47.
    Kienzler JL, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol 2010 Jan; 50 (1): 50–61PubMedCrossRefGoogle Scholar
  48. 48.
    Hui X, Hewitt PG, Poblete N, et al. In vivo bioavailability and metabolism of topical diclofenac lotion in human volunteers. Pharm Res 1998 Oct; 15 (10): 1589–95PubMedCrossRefGoogle Scholar
  49. 49.
    Simon LS, Grierson LM, Naseer Z, et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009 Jun; 143 (3): 238–45PubMedCrossRefGoogle Scholar
  50. 50.
    Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (PENNSAID) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004 Oct; 31 (10): 2002–12PubMedGoogle Scholar
  51. 51.
    Roth SH, Fuller P. Diclofenac topical solution compared with oral diclofenac: a pooled safety analysis. J Pain Res 2011 Jun 3; 4: 159–67PubMedCrossRefGoogle Scholar
  52. 52.
    Haroutiunian S, Drennan DA, Lipman AG. Topical NSAID therapy for musculoskeletal pain. Pain Med 2010 Apr; 11 (4): 535–49PubMedCrossRefGoogle Scholar
  53. 53.
    Makris UE, Kohler MJ, Fraenkel L. Adverse effects of topical nonsteroidal antiinflammatory drugs in older adults with osteoarthritis: a systematic literature review. J Rheumatol 2010 Jun; 37 (6): 1236–43PubMedCrossRefGoogle Scholar
  54. 54.
    Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med 2004 Oct 11; 164: 2017–23PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.Arizona Research and EducationArthritis Research Laboratory Arizona State University PhoenixUSA

Personalised recommendations